Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Shibasaki, F. Mizokami, Y. Yoshizue, M. Okamoto, M. Mishikawa, T. Noro, Y. Maekawa, K. Senda, T. Yagi, H. Tsuge, Y. Kitagawa, K. Nakashima (Oobu, Japan). Clinical efficacy of arbekacin on MRSA pneumonia by intramuscularly injection. Eur Respir J 2010; 36: Suppl. 54, 3007

Member's Comments

No comment yet.

Related content which might interest you: Therapeutic efficacy of macrolides, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Efficacy and safety of azithromycin vs. clarithromycin for the treatment of community-acquired pneumonia due to legionella pneumophila Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence Year: 2004 Comparisom between imipenem/cilastatin and cefepim for treatment of severe nosocomial pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 53s Year: 2007 Clinical efficacy of bolus versus continuous-infusion of piperacillin-tazobactam in VAP treatment Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Eradication of MRSA ventilator-associated infection with inhaled vancomycin. Source: International Congress 2017 – Hospital-acquired infections: from prevention to treatment Year: 2017 Telavancin vs. linezolid in an animal model of severe MRSA pneumonia Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 Efficacy of sequential intravenous (i.v.) to oral (p.o.) moxifloxacin in hospitalized patients with community-acquired pneumonia (CAP) due to m. pneumoniae or chlamydia spp. Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601724; DOI: 10.1183/13993003.01724-2016 Year: 2017 Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Treatment of nosocomial pneumonia with piperacillin-tazobactam Source: Eur Respir J 2007; 30: Suppl. 51, 53s Year: 2007 Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia Source: Eur Respir J 2004; 24 : 644-648 Year: 2004 Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial Source: Eur Respir J 2004; 23: 921-926 Year: 2004 Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Comparison of immunomodulating effects among clarithromycin, dexamethasone and levofloxacin on the murine model of mycoplasma pneumoniae pneumonia Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis Source: Eur Respir J 2010; 35: 858-864 Year: 2010 Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Source: Eur Respir J 2003; 21: 135-143 Year: 2003 Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601612; DOI: 10.1183/13993003.01612-2016 Year: 2017